Sexual Health

PT-141 (Bremelanotide)

10mg · Lyophilized Powder

$60.00 CAD

PT-141 (Bremelanotide) is a cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) developed from Melanotan II research, FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi. Unlike PDE5 inhibitors that work through vascular mechanisms, PT-141 acts centrally by activating melanocortin receptors in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area.

Research Applications

•Central MC3R/MC4R activation for sexual arousal and desire research

•Central nervous system dopaminergic pathway research (reward/arousal)

•Female hypoactive sexual desire disorder (HSDD) research

•Male sexual dysfunction research via non-vascular central mechanism

•Melanocortin receptor agonism and appetite/arousal intersection research

•Comparative research versus PDE5-inhibitor pathways

VIEW DOSING PROTOCOL →

Compare:PT-141 vs Melanotan II →Kisspeptin-10 vs PT-141 →

1

SHARE

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.